Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high‐grade gliomas期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high‐grade gliomas

Authors:	David Schiff MD Annick Desjardins MD Timothy Cloughesy MD Thomas Mikkelsen MD Michael Glantz MD Marc C. Chamberlain MD David A. Reardon MD Patrick Y. Wen MD

Affiliation:	1. Department of Neurology, Neuro‐Oncology Center, University of Virginia Medical Center, Charlottesville, Virginia;2. The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina;3. Neuro‐Oncology Program, University of California at Los Angeles Oncology Center, Los Angeles, California;4. Division of Neuro‐Oncology, Department of Neurosurgery, Henry Ford Health System, Detroit, Michigan;5. Department of Neurosurgery, Pennsylvania State College of Medicine, Milton S. Hershey Medical Center, Hershey, Pennsylvania;6. Department of Neuro‐Oncology, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, University of Washington, Seattle, Washington;7. Center for Neuro‐Oncology, Dana‐Farber Cancer Institute, Boston, Massachusetts

Abstract:

Keywords:	antiangiogenic therapy cabozantinib glioblastoma high‐grade glioma signal transduction inhibitors